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ABSTRACT
The opioid epidemic is affecting Mississippi’s young to middle-aged adult
population in a profound way. Pharmacotherapy for opioid use disorder (OUD) is the
gold standard treatment. Despite the FDA-approved evidence-based treatment of
pharmacotherapy for OUD, rural areas often lack providers available who will initiate
and provide maintenance of this life-saving medication. For this doctoral project, a 36question survey was developed based on a preliminary literature review. The survey was
disseminated to advanced practice registered nurses (APRNs) in the family and
psychiatric specialties across Mississippi to assess the barriers to APRNs filling the gap
in pharmacotherapy prescribing for OUD. A continuing education program was
developed for the dissemination of the results of the survey, to provide education, and
offer further resources on evidence-based treatment for OUD.
The PICO question investigated for this doctoral project was: Among psychiatric
and family nurse practitioners in Mississippi will a survey of knowledge related to OUD
treatment, perceived barriers in buprenorphine prescribing, and awareness of stigma
reveal, compared to current practice, that APRNs are adequately prepared to undertake a
leadership role in prescribing pharmacotherapy for OUD?
The doctoral project offered insight into the barriers to the provision of
pharmacotherapy for OUD by Mississippi APRNs which guided the continuing education
program developed by the researcher. Providers were not adequately prepared through
graduate education to manage OUD by utilizing evidence-based pharmacotherapy
treatment. Stigma amongst healthcare providers toward this population was apparent
which warrants more education and immersive clinical experiences at the undergraduate
ii

and graduate levels. Reduced practice in Mississippi could interfere with the provision of
pharmacotherapy for OUD by APRNs willing to prescribe it.
Mississippi graduate nursing programs should strive toward the American
Association of Colleges of Nursing’s (AACN) 2018 goal, as noted in Compton and
Blacher (2020), to incorporate pharmacotherapy for OUD in graduate nursing
curriculums to prepare future APRNs to fill the gap in treatment provision for people
with OUD. Education in undergraduate and graduate nursing programs should address
the stigma associated with addiction disorders. Prolonged collaborative agreements
between physicians and APRNs in Mississippi should be re-evaluated and full-practice
authority for APRNs with several years of experience should be granted.
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CHAPTER I - INTRODUCTION
Opioid use disorder (OUD) is widely recognized as a public health threat. OUD
has become a more prevalent diagnosis that is marked by a persistent use of opiates
resulting in clinically significant impairment (Dydyk et al., 2020). The primary identified
reason for the rise in the misuse of opioids is increased access (Hoffman et al., 2019). An
increase in prescription opioid medications as well as greater purity in the manufacture of
heroin, and the addition of illicit fentanyl on the market have all contributed to the
development of the opioid epidemic (Hoffman et al., 2019). With an increase in mortality
and morbidity associated with opioid overdose and a decrease in the average American
life expectancy (Shipton et al., 2018), the opioid epidemic puts a costly burden on our
economic system and welfare of society.
According to Florence et al. (2021), the economic burden related to decreased
quality of life due to OUD and the loss of life as a result of fatal opioid overdose was
estimated to be over a trillion dollars in 2017. Florence et al. (2021) further acknowledge
that healthcare costs associated with OUD include medical expenses in the face of
nonfatal overdoses as well as an increase in office visits and emergency room visits for
care. Further, costs of OUD include lost productivity because of incarceration, reduction
in productive hours, and premature death (Florence et al., 2021). The cost of opioidrelated crime must also be accounted for in terms of increased need for police on patrol,
public legal needs, correctional facilities, and property losses (Florence et al., 2021).
Adequate treatment of those who already have OUD will enhance the quality of life of
these citizens and mobilize them to return as productive members of society.
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According to Foney and Mace (2019), access to mental health and addiction
services in the United States (U.S.) is an ongoing problem despite the high demand for
services. Multiple barriers contribute to the lack of access which includes poor insurance
coverage, long wait times and/or limited options in terms of specialty providers, poor
awareness of where to get appropriate help, and fear of being judged for seeking mental
health and/or addiction treatment services (Cohen Veterans Network and National
Council for Behavioral Health [CVN], 2018). Ensuring access to treatment is key to
managing the opioid epidemic.
Since the Comprehensive Addiction and Recovery Act of 2016 (CARA), advance
practice registered nurses (APRNs) and physician assistants (PAs) are qualified to obtain
a waiver to the Controlled Substance Act so that they may prescribe pharmacotherapy for
OUD within the limitations of individual state certification boards. With APRNs on the
front lines of the opioid epidemic, it is imperative that APRNs be prepared with
information to treat OUD using evidence-based practices (EBP). The problem of access
to treatment necessitates that providers who are eligible to treat patients with OUD be
made aware of resources available to prepare them to actively engage in the initiation of
pharmacotherapy for OUD and manage treatment maintenance for these patients
(Comprehensive Addiction and Recovery Act [CARA Act], 2016).
The Substance Use Prevention that Promotes Opioid Recovery and Treatment Act
of 2018 (SUPPORT) has had a positive impact on access to pharmacotherapy for OUD.
While it removes many restrictions for OUD treatment and regulates opioid medications
to prevent over-prescribing practices, it does two specific things that are noteworthy to
the aim of this project. SUPPORT temporarily requires coverage of pharmacotherapy for
2

those who have Medicaid, and it increases the number of OUD patients that providers
may treat (Substance Use Prevention that Promotes Opioid Recovery and Treatment Act
[SUPPORT], 2018).
New legislation as of April 2021 allows physicians, APRNs, and PAs with a drug
enforcement administration (DEA) number to prescribe pharmacotherapy for up to thirty
patients with OUD without obtaining a specific certification or waiver to treat with
buprenorphine in the office-based setting (Office of the Secretary, Department of Health
and Human Services, [HHS], 2021). The aim of this legislation is to increase the number
of providers offering pharmacotherapy for OUD and to broaden access to patients who
need it.
Background and Significance
The opioid epidemic is an ongoing phenomenon in the U.S. Mississippi does have
a high number of opioids prescribed which contributes to the problem of the opioid
epidemic locally. According to the Mississippi Bureau of Narcotics, 440 people died
from overdoses in Mississippi in the year 2020 (Wood, 2021).
The opioid epidemic is impacting Mississippi’s young to the middle-aged adult
population most profoundly. According to the Mississippi Opioid and Heroin Data
Collaborative (Mississippi Board of Pharmacy, Mississippi Bureau of Narcotics,
Mississippi State Department of Health, Mississippi Department of Mental Health [MBP,
2021) the 2020 opioid treatment admissions in facilities that received some form of
public funding in Mississippi were a total of 2,065. Approximately 42.4 % of the people
who presented for treatment admission involving some forms of opioid abuse were
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between the ages of 25 and 44 years old (MBP, 2021). Whether treatment with
pharmacotherapy was offered is not readily apparent.
Multiple barriers exist that Mississippi needs to address to manage the opioid
epidemic. It is known that in rural health care, sub-specialties such as mental health and
substance abuse treatment, are difficult to access (Moore, 2019). In 2021, the estimated
population of Mississippi was 2,949,965 people. Of this population, approximately
1,557,088 people are living in rural Mississippi (U.S. Department of Agriculture
Economic Research Service [USDA ERS], 2022). Furthermore, Mississippi is estimated
to have a poverty rate of 19.75%, putting Mississippi as the most impoverished state in
the nation (U.S. Census Bureau, 2020) which is yet another layer to addressing the
barriers that exist to treatment for OUD.
Mississippi has addressed the opioid epidemic in several ways. According to the
Mississippi Department of Public Safety, Bureau of Narcotics (2019), in December 2016
a task force was initiated by Governor Phil Bryant to address the epidemic with a
strategic plan. Recommendations for future legislation and regulatory measures were
made by the task force to minimize the number of Mississippi citizens falling prey to
heroin and opioid addiction. In May 2017 the task force introduced an educational
promotion in town hall meetings across the state. In July 2018 a two-day opioid and
heroin summit was held to further disseminate education on how the opioid epidemic is
affecting Mississippians. Further, a grant was obtained by DMH to distribute naloxone,
an opioid antagonist used to reverse opioid overdose, to 252 agencies statewide. 27
prescription drug drop boxes were also purchased by DMH thus giving patients with
prescription opioids a place to safely discard these drugs that can easily be diverted and
4

misused. The department has plans for acquiring an additional 37 drug drop boxes to
make these readily available for the safe disposal of opioids across the state
(Mississippi￼￼Department of Public Safety, Bureau of Narcotics [MDPS], 2019).
Mississippi has a large rural citizenship for which provider accessibility and
treatment for OUD are both lacking. Mississippi must address the lack of providers who
are knowledgeable and prepared to initiate and provide maintenance pharmacotherapy to
treat OUD. According to MBP Pearl River County, which is approximately 70% rural
and 30% urban, there were zero naloxone administrations during the year 2020.
Subsequently, there were 21 opioid-related deaths in that county during the same year
(MBP, 2021). While this county did not suffer the most opioid-related deaths in
Mississippi in 2020, the lack of resources is apparent with only two providers listed on
the Substance Abuse and Mental Health Services Administration’s buprenorphine locator
(Substance Abuse and Mental Health Services Administration [SAMHSA], 2022). One
dual-certified nurse practitioner and one family medical doctor are listed as available
outpatient buprenorphine providers in Pearl River County (SAMHSA, 2022). It is not
apparent whether maintenance treatment of OUD, the gold standard for OUD, is offered.
In contrast, MBP (2021) reports that Harrison County, which is approximately
70% urban, had over 49 deaths due to opioid overdoses in 2020. Of the 2,065
administrations of naloxone by emergency medical services in the state of Mississippi for
that year, 443 of these occurred in Harrison County (MBP, 2021). In this well-populated
area, there are 26 providers listed on the buprenorphine locator with 13 of the providers
listed as APRNs or PAs (SAMHSA, 2022). APRNs and PAs must be associated with a
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physician to practice in this reduced licensure state which, presumably, acts as a barrier to
APRNs utilizing the waiver to the maximum extent.
Studies indicate that of two million Americans with OUD only about 26% receive
treatment (Duncan & Reynolds, 2020). “From April 2017 to January 2019, only half of
the clinicians who had met stringent federal requirements and were, therefore, eligible to
prescribe buprenorphine for OUD did so” (Duncan & Reynolds, 2020, para. 3). Duncan
and Reynolds (2020) go on to report that of those who did prescribe buprenorphine, most
were doing so for many fewer patients than the maximum allowed. Under-utilization of
this evidence-based practice (EBP) is a problem that needs to be explored at the state
level with specific interventions tailored to address the barriers that are revealed.
Patients with substance use disorders (SUD) have poor access to treatment,
especially in rural areas (Moore, 2019). The issue is that pharmacotherapy for OUD, also
known as medication-assisted treatment (MAT), is the gold standard for treatment, yet it
is not readily available due to multiple barriers (Atterman et al., 2017). MAT has been
shown to reduce drug use and the risk of overdose as well as preventing ongoing risky
behaviors such as criminal acts and injection use (Atterman et al., 2017). Because
pharmacotherapy is the best EBP for the treatment of OUD, it is necessary to utilize this
practice to the extent of current resources and expand resources to ensure patient
accessibility.
According to one study done by Jones and McCance-Katz (2018),
4,225 clinicians in a sample that included medical doctors, APRNs, and
PAs, “the percentage of clinicians prescribing buprenorphine at or near the patient limit in
the past month was 13.1% overall” (p. 473). Furthermore, approximately 41% to 47% of
6

those prescriptions were in urban settings as opposed to a lower percentage of
approximately 22% to 27% prescribed in the rural settings that were sampled (Jones &
McCance-Katz, 2018). Medical schools and nursing schools do not necessarily devote
education toward the achievement of understanding drug addiction and treatment.
However, the Drug Addiction Treatment Act (DATA) 2000 waiver provides training on
prescribing buprenorphine for OUD (Aaron, 2019). “From 2016 to 2019 the number of
waivered clinicians per 100,000 population in rural areas increased by 111 percent. NPs
and PAs accounted for more than half of this increase and were the first waivered clinicians
in 285 rural counties with 5.7 million residents” (Barnett et al., 2019, p. 2048). Most
waivered APRNs are providing care in urban areas (Moore, 2019); rural areas continue
without access to treatment.
One of the barriers to address is the lack of providers in rural areas that remain
unaware of their eligibility to prescribe, are unable to prescribe, or are unwilling
to prescribe pharmacotherapy initiation and maintenance for OUD. APRNs and PAs have
led the way in the opioid epidemic by becoming waivered to provide pharmacotherapy.
For APRNs to continue to fill the gap in care, it is necessary for graduate nursing
programs to teach the skill of prescribing pharmacotherapy for OUD.
The PICO question formulated from the problem identified is as follows: (P)
Among psychiatric and family nurse practitioners in Mississippi (I) will a survey of
knowledge related to OUD treatment, perceived barriers in buprenorphine prescribing,
and awareness of stigma reveal (C) compared to current practice (O) that APRNs are
adequately prepared to undertake a leadership role in prescribing pharmacotherapy for
OUD in Mississippi?
7

A survey of family nurse practitioners (FNPs) and psychiatric mental health nurse
practitioners (PMHNPs) in Mississippi was done to address knowledge of OUD, EBP for
treatment, and interest pertaining to prescribing treatment for patients with OUD. An
inquiry was done to assess whether APRNs in Mississippi were aware of the new
legislation allowing APRNs to prescribe buprenorphine pharmacotherapy for OUD for up
to 30 patients without earning the certification previously required. For the purposes of
this doctoral project, a continuing education program that took into consideration the
specific needs identified from the survey responses. Lastly, information was provided
about the Provider’s Clinical Support System (PCSS) in the continuing education
program, so that providers can access information and support related to prescribing
pharmacotherapy which includes the free training to become waivered to provide MAT.
The outcomes of the survey include that APRNs in Mississippi identified lack of
education in preparation for prescribing OUD pharmacotherapy. Knowledge of stigma,
both internal bias and identification of external bias, was revealed. The survey offered
insight into the barriers to the prescription of pharmacotherapy for OUD in Mississippi
which guided the continuing education program development. The hope is that the
continuing education program geared toward the needs of Mississippi APRNs will
increase the number of APRNs, across specialties, who apply for the waiver to expand
patient accessibility to pharmacotherapy in their practices. Another outcome that is hoped
for is that those who already have the waiver increase patient load to the maximum
capacity allowable through the waiver.
Lastly, it was one aim of this doctoral project for Mississippi educational
institutions of nursing to incorporate a standard educational practice to incorporate SUD
8

training. OUD pathophysiology and treatment guidelines, taught at the undergraduate,
graduate, and doctoral levels of training for nurses, would be of great benefit to APRN’s
on the frontlines of the opioid epidemic. Exposure to patients with OUD at all levels of
training, such as nursing students having clinical placements in harm reduction programs,
would greatly lessen the stigma associated with OUD and other SUDs.
The doctoral project is linked to the proposed intervention in this way: APRNs
who are on the front lines of the opioid epidemic, FNPs in rural health primary care
clinics, and PMHNPs, may not be aware of the strong evidence-based treatment of OUD
with pharmacotherapy. The problem of access to treatment necessitates that providers
who have a DEA number treat patients with OUD pharmacotherapy as they encounter
them in practice. To do so, they must be made aware of resources to expand their
knowledge so they can safely engage in the treatment and ongoing management of this
disorder given new federal legislation that expands eligibility.
Sources of data used to evaluate the doctoral project outcomes included national
and state collaborative projects. SAMHSA's buprenorphine provider database
(SAMHSA, 2022) was used as one source of data to determine current providers of
pharmacotherapy for OUD. Mississippi Board of Nursing (BON) was used as a source of
data on family and psychiatric APRNs currently holding licensure in Mississippi.
Needs Assessment
Research is needed on the knowledge base of Mississippi primary care,
acute care, emergency medicine, and rural healthcare providers on OUD and evidencebased treatment. Primary care venues are on the front lines of the opioid epidemic
(Bachuber et al., 2016), therefore it is important that pharmacotherapy be prescribed in
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such a setting, especially in rural areas, where limited mental health and substance abuse
treatment resources are accessible. It is also important to determine the current practices
of MAT wavered providers in Mississippi to discern what barriers exist to prescribing
MAT. A concern that must be addressed is whether there are enough physicians with a
DEA number willing to work with APRNs so that APRNs can effectively treat OUD
patients with pharmacotherapy.
Furthermore, the knowledge base of staff who encounter emergency
room patients with opioid overdoses is certainly a critical area to target. Education of
emergency department staff on OUD and the efficacy of pharmacotherapy is imperative
as these patients may experience high levels of stigma associated with their SUD in
an environment where they may be seen repeatedly. The foundational issues that
arise include the need for education about OUD and a need for access to treatment. While
there is a need for more availability of pharmacotherapy initiation, appropriate referrals
for ongoing maintenance are also a necessary part of this gold standard of treatment.
Education on multiple fronts is a key component of conquering the
opioid epidemic. Key areas of education include community education on the danger of
opioid use, education of patients with OUD on evidence-based treatments, and education
of potential prescribers of MAT on the efficacy of MAT. Taking that a step further, some
degree of standardization of the delivery of buprenorphine for the treatment of OUD
also needs to be addressed (Mississippi Department of Health [MDH], 2019). Despite an
increase in those who prescribe buprenorphine, many are not prescribing for longterm maintenance as is needed to ensure the availability of appropriate evidencebased addiction treatment (MDH, 2019). Standardization requires more research on how
10

long MAT should be continued and, in general, studies are showing individualized
treatment for long-term and life-long maintenance is needed (O'Neil, 2014).
Synthesis of Evidence
Search
The aim of the literature search was to identify barriers to access MAT treatment
for OUD. All studies, including gray literature such as unpublished manuscripts and
conference presentations, were eligible for inclusion. Multiple computerized databases
using Seymour Information resulted in numerous articles. Medline, Ebsco Host, and
CINAHL were also utilized independently of Seymour Information. Seymour Information
resulted in 64,905 results for the term, opioid use disorder, and 115,661 results for the
term, medication-assisted treatment. Combining terms resulted in 12,376 results. The
search was narrowed to 2017-2021 resulting in 8,998 results with the added qualifier of
including only articles. The qualifier yielded 7,222 results. Adding the terms nursing and
access yielded 1,137 results. Removing the term pain from the subject list and refining
the search again to the phrase, substance abuse treatment articles, led to 331 results.
Seymour Information was utilized to search barriers to buprenorphine prescribing.
The search was narrowed refining the subject to buprenorphine, between the years 2017
and 2021 with 62 results. Substantial literature suggested that barriers to access the gold
standard treatment perpetuate the opioid crisis in the U.S. Specifically, research findings
suggested that prescribing restrictions, addiction treatment being regarded as a specialty
care practice, financial barriers, stigma of SUD, and bias toward the use of
MAT contribute to the limited accessibility that remains.
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Other sources were sought independently of the systematic search of the
literature. State and federal resources were utilized to determine the extent of the problem
of opioid use in Mississippi and on a national level. Additionally, references from articles
found in the literature review were scanned for useful information.
The literature regarding barriers to access pharmacotherapy for patients with
OUD was explored in articles from interdisciplinary fields in nursing and medicine
spanning five years, from 2017 to 2021, using key words that included: buprenorphine,
medication-assisted treatment (MAT), prescribing, barriers, access, opioid use disorder
(OUD). The specific aims were to determine what barriers associated with MAT for
OUD were represented in the literature, (b) to assess what the literature addresses to
overcome the barriers identified, and (c) to extrapolate identified needs in the literature.
Definition of Key Terms
Opioid use disorder (OUD) is defined in the Diagnostic and Statistics Manual
(DSM V) (American Psychiatric Association [APA], 2013) as repeated use of opiates
resulting in the clinical impairment of functioning in multiple domains. The criteria
continue to identify eleven symptoms of which a person manifests at least two within the
last 12-month period. The symptoms include increasing the dosage of opioids or taking
them longer than prescribed, having an ongoing desire to stop or control use without
success, spending a significant amount of time trying to obtain or recover from opiates,
having cravings for opiates, and/or using the drug interferes with the fulfillment of
responsibilities at work, school, or home. Continued opioid use regardless of the ongoing
problems in one’s social life for which opiate use is the cause, giving up or not engaging
as often in social, recreational, or occupational activities because of opiate use, using
12

opioids in physically harmful situations, using opioids even though one has the
knowledge that they are contributing to physical or psychological problems, opioid
tolerance, and/or opioid withdrawal (APA, 2013).
Substance use disorder (SUD) is defined by the DSM V (APA, 2013) diagnostic
criteria to encompass ten individual classes of drugs. Alcohol; caffeine; cannabis;
hallucinogens (phencyclidine or similarly acting arl-cyclohexylamines; and other
hallucinogens); inhalants; opioids; sedatives, hypnotics, or anxiolytics; stimulants
(amphetamine-type substances, cocaine, and other stimulants); tobacco and other
unknown substances are listed as separate classes of drugs (APA, 2013). Therefore, SUD
includes the diagnosis of OUD.
Medication-assisted treatment (MAT) is defined by SAMHSA (2022) as the use
of medication and behavioral interventions to treat SUDs. MAT includes methadone in
opioid treatment programs and buprenorphine/naltrexone in outpatient
settings. (SAMHSA, 2022.) This term is utilized when used in the context of an article
that adheres to the use of this term; otherwise, the term pharmacotherapy will be used.
Pharmacotherapy is a more accurate term used to identify the use of medications
in the treatment of SUD. According to Robinson and Adinoff (2018), the utilization of
the term MAT is inherently confusing because it gives the message that pharmacotherapy
is ancillary rather than first-line treatment for OUD. This mixed message reinforces
archaic ideation and stigma in opposition to OUD pharmacotherapy (Robinson &
Adinoff, 2018). For this reason, the preferred term to describe medication that is
prescribed in the treatment of OUD is pharmacotherapy.
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Evidence-based practice (EBP) is an approach to treatment utilizing the best
evidence for practice. Three benchmark domains are utilized to evaluate evidence:
quality, quantity, and consistency (Tymkow, 2021). The presence of high-quality
evidence indicates the lack of bias present as a result of errors in the selection,
measurement, or internal validity. Quantity, as it relates to evidence, refers to the actual
number of relevant and related studies, total sample sizes across studies, size of the
treatment groups, and relative risk. Consistency points to the recurrence of similar
findings across multiple studies that have statistical significance (Tymkow, 2021).
Advanced practice registered nurses (APRN) as defined by the American Nurses
Association (n.d.) includes nurse practitioners, nurse anesthetists, nurse midwives, and
clinical nurse specialists; all of which have an advanced degree of a master’s level or
doctorate level education. The role of APRNs is to diagnose and treat illness, promote
patient health at various levels and stages of development, and engage in continuous
education to ensure offering well-informed treatment at the individual and community
level (American, Nurse’s Association [ANA], n.d.).
OUD and Pharmacotherapy
OUD is a widely recognized public health threat in the United States. The
National Center for Drug Abuse Statistics [NCDAS] (2019) notes that fentanyl was a
factor in over 50% of overdose deaths in the U.S. in 2020. NDCAS (2019) also noted that
the overdose deaths since 2020 have increased by 26.8% to more than 88,000 deaths with
a disproportionate effect on working adults between ages 25-54 who have families that
rely on them. Mississippi Prescription Monitoring Program data for 2020 notes that there
were 443 overdose deaths and 2,065 naloxone administrations for that year. Patients
14

seeking OUD treatment in federal programs alone in Mississippi during the quarters
one through three of the year 2020 amounted to 2,196 patient admissions (Mississippi
Board of Pharmacy, Mississippi Bureau of Narcotics, Mississippi State Department of
Health, Mississippi Department of Mental Health, &The University of Southern
Mississippi [MBP], 2020).
The Mortality and Morbidity Weekly Report notes that overdose deaths were
approximately 12 times higher in 2019 than in 2013 for mortalities associated with
synthetic opioid overdose (Mattson et al., 2021). Over 36,000 people overdosed and died
using synthetic opioids in 2019 (Mattson et al., 2021). Furthermore, NCDAS (2019)
notes that in Mississippi opioids are prescribed in the case of an estimated 55.8% of all
overdose deaths and just over 41% of deaths involving synthetic opioids such as
fentanyl.
Tertiary prevention should focus on expanding evidence-based treatment of
OUDs and reducing the harms of ongoing opioid use (Tsai et al., 2019). The efficacy of
pharmacotherapy for OUD is well documented throughout the literature (Atterman et al.,
2017; Parker et al., 2018; Vestal, 2018). Vestal (2018) notes that patients in recovery
utilizing pharmacotherapy treatment for OUD are twice as likely to succeed without
relapse. MAT is a wise investment for two identified reasons according to Parker et al.
(2018). First, the benefits of prescribed pharmacotherapy for the treatment of OUD
outweigh the expense incurred. In this way, treatment is said to meet the costeffectiveness standard. Second, healthcare costs are lower in patients treated undergoing
pharmacotherapy for OUD in comparison to those treated without. The expansion of this
EBP would most definitely enhance patient outcomes which is why federal efforts target
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the barrier of poor access. Limitations to access of pharmacotherapy for OUD are a major
issue in the continued growth of the opioid epidemic (Jackson & Lopez, 2018; Jones,
2018; Ober et al., 2017; Parker et al, 2018; Walley et al., 2008).
Barriers to Access
Multiple barriers have been identified to explain the lack of access to EBP for
OUD. Prior authorization requirements, lack of staff, and psychiatric specialty providers
were indicated as barriers to the provision of pharmacotherapy for OUD by Kermack et
al. (2017). Other identified barriers include prescribing restrictions (Andrilla et al., 2020;
Germack, 2021; Jackson & Lopez, 2018) lack of knowledge of where to refer patients for
treatment (Barnett et al., 2019; Jones, 2019; Jones & McCance-Katz, 2018; Moore,
2019), addiction treatment as a specialty care practice (Bachhuber et al., 2016; Gardenier
et al., 2020; Logan et al., 2019), financial concerns (Andrilla et al., 2020; Gardeneir et al.,
2020; Kermack et al., 2017; Motjabi et al., 2019), the stigma associated with SUD and
MAT (Cadet & Tucker, 2019; Compton, 2020; Haffajee et al, 2020; Jones et al., 2020;
Kameg & Mitchell, 2020; Madden, 2019; Poorman, 2021; Scott et al, 2020; Slawek et al.,
2019), lack confidence in treating patients with OUD (Molfenter et al., 2017), and
concerns about a diversion (Andrilla et al., 2020). Recommendations for healthcare
education surrounding SUD are documented to enhance access to this life-saving
treatment (Finnell et al., 2019; Tierney et al.,2020; Tsai et al., 2019; Webster et al.,
2018).
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Prescribing Restrictions
APRNs in Mississippi are required to be in collaborative agreement with a
physician which restricts practice by imposing a limitation on access to
treatment. Mississippi is fiftieth in the nation for physician shortage. Primary care
physicians are lacking across the nation, more likely to go into more specialized practice
for financial compensation. APRNs can fill the gap as primary care providers, especially
in rural areas. Gardeneir et al. (2020) explain that “although NPs are now providing care
in many rural areas, more than half of rural counties have no provider” (p. 174).
Limitations on APRNs in reduced practice and restricted practice states influence the
extent to which APRNs can improve access to healthcare in under-served areas. Full
practice authority for experienced APRNs in Mississippi could offer treatment access to
patients with OUD.
The prescribing of buprenorphine by APRNs and PAs would improve access if
state limitations on prescribing were eliminated (Jackson & Lopez, 2018). Andrilla et al.
(2020) make note that APRNs and PAs are projected to increase the number of rural
patients in treatment for OUD by approximately 15.2%. Germack (2021) advocates
scope of practice restrictions to be lifted for NPs to fill the treatment gap as needed.
Cos et al. (2021) discuss the evidence of policy and care barriers that contribute to
the lack of access to MAT and the practice recommendations that may lead to enhanced
care delivery by APRNs. It is noted, among other common barriers, that practice
authority for APRNs in individual states is a barrier to healthcare service delivery of
buprenorphine. Only 26 states in the United States (U.S.) allow full practice
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authority. Cos et al. (2021) acknowledged that the problem of individual state restrictions
on the scope of practice for APRNs is an issue that is amplified in rural settings.
According to a study done by Jones and McCance-Katz (2018), of 4,225
clinicians in a sample that included medical doctors (M.D.s), APRNs, and PAs, “the
percentage of clinicians prescribing buprenorphine at or near the patient limit in the past
month was 13.1% overall” (p. 473). Furthermore, 41.6%-47.2% of those prescriptions
were in urban settings as opposed to a lower percentage of 22.3%-27.4% being
prescribed in the rural settings sampled (Jones & McCance-Katz, 2018). “From 2016 to
2019 the number of waivered clinicians per 100,000 population in rural areas increased
by 111 percent. APRNs and PAs accounted for more than half of this increase and were
the first waivered clinicians in 285 rural counties with 5.7 million residents” (Barnett et
al., 2019, p. 2048). Most waivered APRNs are providing care in urban areas (Moore,
2019). While there is an increase in providers of pharmacotherapy for OUD, the gap
continues to widen as the number of patients with OUD increases.
The Medicaid and CHIP Payment and Access Commission (2019) contracted with
IMPAQ International to look at prescribing patterns of buprenorphine by APRNs
following the implementation of the Comprehensive Addiction and Recovery Act of
2016 (CARA). CARA authorizes APRNs and PAs to prescribe buprenorphine in officebased settings for the treatment of OUD. The number of buprenorphine prescriptions was
shown to increase during the study period from July 2017 to July 2018 with a 12%
increase noted among the Medicaid population. The patterns suggest that expanded
prescribing authority for APRNs directly resulted in an increase in prescriptions for MAT
(Medicaid and CHIP Payment and Access Commission [MACPAC], 2019).
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In summary, limitations to practice authority for APRNs are a barrier to MAT
access (Cos et al., 2021; Jackson & Lopez, 2018). While APRNs and PAs have led the
way in the expansion of MAT (Barnett et al., 2019), they are limited by whether there is a
physician with a DEA number that is willing to maintain a collaborative agreement, as is
the requirement in reduced practice states according to the American Association of
Nurse Practitioners (n.d.), such as Mississippi. The issue of stigma associated with SUDs
and pharmacotherapy as a viable treatment remains one of the multiple barriers discussed
later. Physicians, like APRNs, do not have standardized or required curricula
incorporated into medical training, as will be explored later in this section. This lack of
education on the evidence-based pharmacotherapy treatment of OUD also contributes to
limited access.
Poor Knowledge of Resources for Treatment
Nineteen percent of providers in a study identified lack of patient demand as a
reason why they were not treated to the maximum capacity of the DATA 2000 X waiver
(Jones, 2019). Jones (2018) reports this could reflect the lack of knowledge in the
community about EBP for OUD, lack of referral communication, and could be impacted
by various levels of stigma.
Retention in treatment for OUD is a barrier addressed by Hoffman et al. (2019).
The problem of patients transitioning from one level of care to another is a problem for
patients to maintain recovery. Daily dosing is another barrier to retention that Hoffman
(2019) identified. Preparations of naltrexone as an extended-release formula for monthly
use as well as a monthly buprenorphine injection and implantable buprenorphine have
been developed to address that issue, though, limitation to their access remains a barrier
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(Hoffman et al., 2019). In a study of rural participants using MAT in New
Mexico, Scorsone et al. (2020) note that patients maintained on buprenorphine described
avoiding withdrawal from buprenorphine as motivation to maintain treatment although
they felt conflicted about being dependent on it to maintain recovery.
Finnegan (2019) references an increase in primary care physicians who are taking
on buprenorphine prescribing according to a study done on the trends in buprenorphine
prescribing by physician specialty. In the study, Wen et al. (2019), using the National
Ambulatory Care Medical Survey from 2006-2014, and an unweighted sample size of
over 300,000 patients was reviewed. Trends suggest that buprenorphine prescribing
practices increased during the period and non-psychiatric specialties were driving this
trend (Wen et al., 2019).
Lack of knowledge in the community regarding whom or where patients with
OUD should be referred for treatment is a barrier to access. While non-psychiatric
specialties such as primary care physicians (PCPs) have increased utilization of
buprenorphine prescribing practices to treat OUD (Finnegan, 2019; Wen et al., 2019),
patients have a difficult time with retention in treatment. In addition to the stigma and
lack of knowledge of how to adequately treat OUD (addressed later in Chapter I), another
problem that patients face is a lack of continuity of care from one treatment environment
to the next (Hoffman et al., 2019). Because patients maintained with buprenorphine
suffer opiate withdrawal and subsequent relapse, ensuring a patient makes a successful
transition from one level of care to the next with buprenorphine maintenance needs to be
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Addiction Treatment as Specialty Care
While Wen et al. (2019) note that access to treatment for OUD is more accessible
in settings alternative to the addiction treatment specialty than it has been in the past,
much evidence points to the ongoing delegation of primary care referrals of OUD
treatment to addiction specialists due to provider stigmatization of SUD (Hawk &
D’Onofrio, 2018; Knudsen et al., 2011; Lister et al., 2020; Madden, 2019; Poorman,
2021; Stone et al., 2021) and lack of knowledge (Haffajee et al., 2020; Scott et al., 2020;
Slawek et al., 2019) in the course of treatment. However, “the vast majority of NPs
provide primary care, and many of us practice in communities that have higher rates of
OUD, more numerous barriers to care, and fewer services, positioning us as a profession
to have a major impact on this crisis” (Gardenier et al., 2020, p. 174).
Successful integration of addiction treatment into primary healthcare clinics has
been documented by Logan et al. (2019). Comorbid medical conditions associated with
OUD can be well treated with the utilization of a holistic perspective in such integrated
treatment clinics. Primary care venues are on the front line of the opioid epidemic
(Bachuber et al., 2016).
Rural regions lack specialty service availability such as mental health and SUD
treatment providers and are geographically positioned further from treatment facilities
(Scorsone et al., 2020). In a study, more rural providers indicated a lack of specialty back
up and fewer mental health specialty providers as a barrier to treatment access (Andrilla
et al., 2020). Integrated care utilizing telehealth could expand access to treatment of SUD
as has been done with mental health, but Huskamp et al. (2018) point out that low rates of
tele-SUD use are an opportunity missed.
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In a comprehensive review of OUD by Dydyk et al., (2020), the authors
emphasize that healthcare professionals need to take an inter-professional approach to
manage patients with OUD. Emergency department providers, for example, can initiate
pharmacotherapy for OUD and refer to community mental health, addiction specialists,
and/or primary care practices that engage in pharmacotherapy maintenance for OUD in
the community. A review of the literature on emergency department screening and
interventions implemented in the setting for SUD was reported on by Hawk and
D’Onofrio (2018). Among the findings for effective management of SUD screening,
implementation of MAT, and appropriate referral was the issue of providers having
competing priorities (Hawk & D’Onofrio, 2018).
When addiction is viewed as a specialty treatment area, primary care providers
miss the opportunity to engage patients in EBP for OUD treatment where appropriate.
Non-psychiatric treatment professionals have expanded to incorporate pharmacotherapy
for OUD (Wen et al., 2019). However, the expansion has not yet met the demand for
pharmacotherapy services. While patients with co-morbid psychiatric and SUD treatment
can legitimately be viewed as a complex course of treatment that should be undertaken
with the skill of a psychiatric specialist, primary care providers (Bachuber et al., 2016;
Gardenier et al., 2020) and emergency department providers (Hawk & D’Onofrio, 2018)
are in prime positions to implement pharmacotherapy for OUD. Primary care APRNs are
at the frontlines of treatment, especially in rural areas (Bachuber et al., 2016; Gardenier et
al., 2020) where access to pharmacotherapy is most needed.
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Financial
Provider concerns about reimbursement present a barrier to offering MAT
(Kermack et al., 2017). Patients in rural areas rely more on Medicaid which is known for
low reimbursement rates. Mississippi Medicaid has not expanded, which has left patients
uninsured and without the benefits offered by the federal government incentives.
Expansion of Medicaid coverage has been purported to have the potential in alleviating
barriers to accessing MAT in underserved areas (Mojtabi et al., 2019). Rural areas are
often without specialty providers such as mental health and addiction treatment (Moore,
2019) reflecting how rural health disparities influence the availability of
pharmacotherapy for OUD treatment (Jones, 2018; Vohra et al., 2020). Inequalities in the
accessibility of pharmacotherapy for OUD are more pronounced in rural communities
(Cos et al., 2021).
Cos et al. (2021) note the issue of reimbursement for behavioral therapy conflicts
with medication management services as a concern for providers. The maintenance and
upkeep that are required to provide MAT are not reimbursable services in many cases.
The conflict in reimbursement and limitations to funding both acts as barriers to provider
willingness to take on pharmacotherapy treatment of OUD (Cos et al., 2021).
Madras et al. (2020) note that financial barriers contribute to the limited access to
care for many patients with OUD. Madras et al. (2020) recommend several strategies to
remedy this problem such as the expansion of Medicaid throughout all states. All FDAapproved medications for OUD should be accessible through public and private payers.
Incarcerated individuals should be able to access MAT utilizing Medicaid funds and have
access to appropriate care immediately upon release (Madras et al., 2020).
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Income-related impediments are a barrier for people living in rural areas that are
looking for OUD treatment (Scorsone et al., 2020). Scorsone et al. (2020) also point out
the issue of poor insurance coverage for people in rural areas. Knudsen et al. (2011)
utilized telephone interviews with 250 administrators of publicly funded SUD treatment
facilities to examine barriers to MAT initiation. Findings indicated that primary funders
would not pay for the purchase of medications or lab equipment and testing. Lack of
physician time was another noted barrier. Another financial-related barrier noted in this
study was that patients were unable to pay for MAT without assistance (Scorsone et al.,
2020).
Multiple barriers exist for specialty health care in rural settings. In a systematic
review of the literature, Lister et al. (2020) examined the rural-specific barriers to MAT
for OUD. Among the barriers identified in addiction treatment, accessibility-related to
cost and travel were noted as a problem.
In a pilot program to increase access to MAT for patients with OUD in rural
Colorado, three clinical agencies in two counties increased the number of providers of
MAT in both counties (Sorrell et al., 2020). They tracked costs, community-level
barriers, and facilitators of success in monthly reports. Barriers that interfered with the
sustainability of the program included issues of reimbursement for MAT (Sorrell et al.,
2020).
Stein et al. (2015) reviewed the number of buprenorphine-waiver
physicians/100,000 county residents between 2008-2011. Using multivariate regression,
they predicted the number of waivered physicians/100,000 residents in a county as a
function of county characteristics, state policies, and efforts to promote MAT. The
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calculation reveals for the year 2011, 43% of US counties had no waivered physicians.
Increased Medicaid funding was one of the factors that contributed to more
buprenorphine-waivered physicians.
Reimbursement for pharmacotherapy was noted as a barrier to access
pharmacotherapy for OUD in multiple studies (Kermack et al., 2017; Knudsen et al.,
2011; Lister et al., 2020; Madras et al., 2020; Scorsone et al., 2020; Sorrell et al., 2020).
Expansion of Medicaid, as suggested by Motjabi et al. (2019) and Stein et al. (2015),
would alleviate some of the financial restrictions associated with reimbursement for OUD
pharmacotherapy. Cos et al. (2021) note the conflict in billing services that require a
resolution so that both behavioral therapy and pharmacotherapy can be issued to patients
with OUD who are seeking EBP addiction treatment.
Stigma
According to Bachhuber et al. (2016), SUD is now recognized as a chronic
condition and OUD pharmacotherapy treatment is a mainstay with behavioral therapy as
an adjunctive treatment in recovery. Poorman (2021) identifies that “a larger barrier to
treatment expansion is cultural: physicians and institutions fail to treat substance use
disorder as the chronic disease they are” (p. 1783). This is representative of the stigma
associated with SUD.
In a study of physician attitudes on treatment for OUD, 77.6% of respondents
recognize OUD as a chronic medical condition like diabetes mellitus, and less than 13%
defined the patient with OUD as having some inherent failing of willpower or being of
less moral character. Over 90% recognized that patients with OUD can be stabilized and
live quality lives with appropriate treatment. Despite the understanding and acceptance
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that OUD is a treatable chronic condition, this biologic model does not curtail the stigma
associated with the disease nor does it entice more providers to engage in its treatment
(Stone et al., 2021). When providers observe their patients’ relapse on multiple occasions,
“a phenomenon exacerbated by ineffective non-medication OUD treatment approaches
may reinforce a sense that all OUD treatment is ineffective” (Stone et al., 2021, p. 5).
Intervention stigma was addressed by Madden (2019) as a barrier to treatment
among patients with OUD. Despite the efficacy of MAT among academics, the addiction
treatment community is not all-embracing this EBP. The stigma associated with the use
of medication as part of treatment for OUD is viewed as taking one drug to cope with the
loss of another. Madden (2019) points out that both patients taking MAT and providers
prescribing MAT, alike, experience bias from other healthcare professionals (nurses,
physicians, social workers), and the general public; all those in the addiction community
that embrace an abstinence-only point of view to SUD treatment deny the benefit of
pharmacotherapy as a treatment for OUD. Scorsone et al. (2020), too, identify a stigma
among healthcare professionals related to MAT initiation. Lack of education across care
settings on OUD treatment promotes the ongoing bias that permeates
various healthcare specialties (Scorsone et al., 2020).
One of the themes that demonstrates ignorance of the pharmacology of heroin and
methadone is that MAT is simply substituting one drug for another without understanding
the risk for relapse associated with the abstinence approach (Woods & Joseph,
2017). Reflection on the studies of Drs. Dole, Nyswander, and Kreek were discussed in
an article authored by Woods and Joseph (2017) which explains how the utilization of
methadone and buprenorphine have changed treatment for OUD. Woods and Joseph
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(2018) acknowledge that there is an abounding misperception that MAT is a substitution
of one drug for another which promotes prejudice against its use. Medication stigma, as
noted in an article by Seppala (2013), and the attitude of abstinence as a treatment for
OUD interferes with the acquisition of a successful long-term recovery. Patients with
OUD are vulnerable after detox and are at higher risk of death from an accidental
overdose due to reduced tolerance (Seppala, 2013).
In a study using random-intercept modeling to identify factors linked to
buprenorphine treatment use over two years, Evans et al. (2019) report that 789
individuals participated in this multi-site randomized clinical trial of buprenorphine
compared to methadone. Evans et al. (2019) found that the acceptability of MAT
influenced whether patients utilized it when it was readily available. A mere 9.3%
to11.2% of participants chose to use MAT. Individuals who perceived buprenorphine use
to be acceptable were more likely to choose MAT while those who perceived it to be
unacceptable chose an abstinence-based recovery (Evans et al., 2019).
Some people may experience more prejudice than others. Stigmatization around
the use of MAT as a legitimate form of treatment for OUD is felt more among patients
with a comorbid diagnosis of psychiatric disorder, HIV/AIDS, or if the patient is a
minority (Cadet & Tucker, 2019). Further barriers addressed by Cadet and Tucker (2019)
include financial concerns, poor confidence among providers interested in treating
patients with OUD, and lack of resources due to regulatory bodies. The continuing
nursing education article proceeds to describe how to combine medication and behavioral
therapy with shared decision-making with the patient seeking treatment for OUD (Cadet
& Tucker, 2019).
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Cos et al. (2021) acknowledge that provider perceptions impact the access
patients have to MAT. The stigma associated with SUD as a condition permeates the
medical community which results in poor utilization of person-centered care and
negatively affects patient outcomes (Cos et al., 2021). In a study of 250 administrators of
publicly funded SUD programs, Knudsen et al. (2011) made note that for about a third of
the responders, barriers to lack of implementation of MAT could be attributed to the
inconsistency of MAT treatment with the SUD facility’s treatment philosophy and/or the
belief that there are better alternatives for the treatment of SUD than MAT provides.
Scorsone et al. (2020) identify a stigma among healthcare professionals related to
MAT initiation. Lack of education across care settings on OUD treatment promotes the
ongoing bias that permeates various healthcare specialties. The therapeutic relationship
that exists between provider and patient can have a profound effect on how patients with
OUD experience bias and whether they access treatment (Scorsone et al., 2020).
The idea that negative attitudes among healthcare providers toward people who
need treatment for SUD influence patient treatment are also noted by Jackman et
al. (2020). To test the impact of an educational strategy on the attitudes of nursing staff
toward patients with SUD, a 22 item was developed to assess the nursing attitudes of
patients before an eight-hour educational workshop followed by a posttest and 30-day
follow-up (Jackman et al., 2020). The results indicated a significant increase in positive
attitudes posttest and sustained through the 30-day follow-up (Jackman et al., 2020).
In a systematic review of the literature, Lister et al. (2020), examined the ruralspecific barriers to MAT for OUD. Among the barriers identified, negative attitudes
toward MAT were pervasive among providers in rural areas, and the perception of MAT
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was viewed as unsatisfactory for rural patients by providers (Lister et al., 2020). In a pilot
program to increase access to MAT for patients with OUD in rural Colorado, three
clinical agencies in two counties increased the number of providers of MAT in both
counties (Sorrell et al., 2020). They tracked costs, community-level barriers, and
facilitators of success in monthly reports. Barriers that interfered with the sustainability
of the program included issues of stigma and coordination with hospitals (Sorrell et al.,
2020).
A review of the literature on emergency department screening and interventions
implemented in the setting for SUD was reported on by Hawk and D’Onofrio (2018).
Findings suggest that stigma interferes with the effective management of SUD screening
and appropriate referral for patients to seek treatment. Bias further impacts the lack of
implementation of MAT in the emergency department setting as well (Hawk &
D’Onofrio, 2018).
Dumenco et al. (2019) performed a qualitative analysis after providing a panel
experience to inter-professional students. The aim was to assess the nursing, pharmacy,
and social work students’ perceptions of patients with OUD based on the
authors' hypothesis that interaction with patients with OUD early in training would
promote a more positive perception. Findings note that 70% of students’ perceptions
changed positively (Dumenco et al., 2019).
A qualitative analysis of nursing students’ experiences and attitudes towards
patients with OUD was conducted by Lewis and Jarvis (2019). Eleven nursing students
from a public university in New England participated in semi-structured interviews on the
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topic. Emerging themes included witnessing discrimination in SUD treatment and care as
well as acknowledging stigma and bias (Lewis & Jarvis, 2019).
Madras et al. (2020) note that healthcare professionals often have stigmatizing
attitudes toward both medications to treat OUD and the condition of OUD itself. The
therapeutic relationship that exists between provider and patient can have a profound
effect on how patients with OUD experience bias and access treatment (Scorsone et al.,
2020). Stigma is an important factor to manage if primary care providers and emergency
department providers are to knowledgeably initiate treatment for OUD and, in the case of
primary care, successfully maintain recovering OUD patients in the outpatient setting.
Webinars were utilized by Cos et al. (2021) in a consortium to explore healthcare
stigma directed toward SUD as a condition. Findings among those that attended revealed
numerous assumptions about patients seeking care. Among the attendees, those who had
training rotations that included SUD treatment with harm reduction (HR)-focused
programs employed less use of stigma toward patients with SUD (Cos et al., 2021). The
strategy suggested by Madras et al. (2020) to impact SUD stigma advises targeted
campaigns for healthcare providers initiated by the Centers for Disease Control and
Prevention (CDC).
Healthcare professionals have been documented to have stigmatizing behaviors
and attitudes toward patients with SUD (Cos et al., 2021; Dumenco et al., 2019; Hawk &
D’Onofrio, 2018; Jackman et al., 2020; Lewis & Jarvis, 2019; Lister et al., 2020; Madras
et al., 2020; Scorsone et al., 2020; Sorrell et al., 2020). The influence that providers have
on patients' willingness to utilize pharmacotherapy in the treatment of OUD is negatively
impacted in the presence of bias (Cos et al., 2021; Madras et al., 2020; Scorsone et al.,
30

2020). Provider stigma interferes with access to pharmacotherapy in rural settings (Lister
et al., 2020) and emergency department screening, implementation of MAT, and referral
provision (Hawk & D’Onofrio, 2018). In SUD programs, the issue of adhering to
abstinence-only standards of treatment for OUD, as is noted in the Knudsen (2011) study,
sets patients up for failure in their recovery and puts them at a higher risk of accidental
overdose with relapse (Seppala, 2013).
In summary, stigma is a major barrier to accessing treatment because providers
fail to recognize OUD as the chronic disorder that it is (Poorman, 2021) and employ an
abstinence-only treatment strategy for OUD without paying heed to the groundbreaking
treatment options of methadone and buprenorphine for OUD (Woods & Joseph, 2017).
When providers utilize ineffective non-medication approaches to treat OUD and fail, this
perpetuates the myth that OUD treatment is just not effective (Stone et al., 2021). Stigma
toward OUD and toward the medications used to treat it are pervasive in the medical
community, especially among those that adhere to the abstinence-only motto (Madden,
2019).
Lack of Provide Education
Compton and Blacher (2020) acknowledge that the American Association of
Colleges of Nursing (AACN, 2018) set a future goal of having nursing schools include
opioid use education in the curriculum for upcoming nurses. Education and training of
primary care providers would be of benefit to alleviate the issue of treatment access (Lee
et al., 2015). Physicians identify a lack of knowledge regarding EBP initiation (Haffajee
et al, 2020; Scott et al, 2020; Slawek et al., 2019) and a lack of confidence in
managing patients with OUD as barriers to offering treatment (Molfenter et al., 2017).
31

APRNs and PAs identified their most common concern about prescribing
buprenorphine for OUD treatment was the issue of diversion (Andrilla et al., 2020). An
educational intervention to expand the knowledge of MAT among VA providers resulted
in the incorporation of MAT as an option for eligible patients in VA facilities (Jones et
al., 2020). Kameg and Mitchell (2020) utilized marketing to offer a three-part series on
opioid use management and surveys were disseminated for feedback. Barriers to
buprenorphine prescribing identified in the Kameg and Mitchell (2020) study were
categorized into regulatory factors, patient-specific factors, and provider-specific
factors. Undergraduate, graduate and continuing education programs for medical and
nursing professionals have been recommended (Tsai et al., 2019).
Madras et al. (2020) note that healthcare providers often lack the training to
prescribe MAT for OUD. The strategy suggested indicates that credentialing agencies for
physicians, PAs, and APRNs should require these clinicians to undergo training in
screening, diagnosis, and treatment of OUD (Madras et al., 2020).
Knudsen et al. (2011) in a study interviewing 250 administrators of publicly
funded SUD programs note key barriers to the lack of adoption of pharmacotherapy for
OUD. One such barrier was the lack of access to medical personnel who had specific
expertise in providing MAT. About a third of the responders noted that adequate
information about how to implement MAT was not received by the program (Knudsen et
al., 2011).
In a comprehensive review of MAT for OUD, the National Academies of
Sciences, Engineering, and Medicine, Health and Medicine Division of the Board of
Health on Health Sciences Policy (2018) notes barriers to MAT implementation.
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Addiction content was added to the university curriculum at Yale throughout medical
training. Addressing the stigma associated with SUD that is prevalent among medical
providers is an important aspect of medical training. Correcting the use of stigmatized
language associated with SUD and its treatment in necessary early in medical school.
Education and training directed toward medical providers would enhance the engagement
of medical students in the effort to combat the opioid crisis. (National Academies of
Sciences, Engineering, and Medicine; Health and Medicine Division; Board of Health on
Health Sciences Policy [NASEM], 2018).
A review of the literature on emergency department screening and interventions
implemented in the setting for SUD was reported on by Hawk and D’Onofrio (2018).
Among the findings for effective management of SUD screening, implementation of
MAT, and appropriate referral was the issue of inadequate training in providing treatment
for addiction (Hawk & D’Onofrio, 2018). Inadequate training for emergency department
providers needs to be addressed as it is a frequent point of access to care for patients most
in need of pharmacotherapy.
A qualitative analysis of nursing students’ experiences and attitudes towards
patients with OUD was conducted by Lewis and Jarvis (2019). Eleven nursing students
from a public university in New England participated in semi-structured interviews on the
topic. Themes included ethical concerns, gaining comfort with time, and gaining
experience through active engagement instead of avoiding the necessary subject of
addiction with the patient (Lewis & Jarvis, 2019).
Lack of provider education regarding SUD and treatment, specifically for OUD,
was noted in multiple studies to act as a barrier to patient access to pharmacotherapy
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(Haffajee et al, 2020; Hawk & D’Onofrio, 2018; Madras et al., 2020; Scott et al, 2020;
Slawek et al., 2019). Lack of confidence in initiating pharmacotherapy for OUD, in the
maintenance of treatment (Knudsen et al., 2011) presents limitations to access.
Furthermore, lack of experience in openly discussing addiction (Lewis & Jarvis, 2019)
offers another explanation for the reasoning that providers do not prescribe
pharmacotherapy.
Educational interventions have shown to be of benefit (Kameg & Mitchell, 2020)
when utilized in organizations such as the VA where pharmacotherapy (Jones et al.,
2020) is now an option for patients. Educational interventions are beneficial when
incorporated into the university curriculum (NASEM, 2018). It is the goal of AACN to
have nursing programs at all levels incorporate SUD and OUD treatment in curricula
across the U.S. (Compton & Blacher, 2020), and is recommended by other sources
(NASEM, 2018; Tsai et al., 2019).
Nursing Education
Training in medical, nursing, and pharmacy education on OUD and MAT has
been limited but is gradually being incorporated into the education of health professionals
(O’Neil, 2014). Nursing was one of the first health professions to acknowledge that
education on substance use is lacking (Tierney et al., 2020). Specific SUD competencies
tailored to nursing practice such as Project Mainstream published by the Association for
Medical Education and Research can be used by APRNs in public health and generalist
practice to effectively employ screening, brief intervention, and referral to treatment
which is collectively known as SBIRT (Tierney et al., 2020). The American Academy of
Nursing supports that nurses across specialties and settings can and should lead the
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practice by identifying and screening patients for potential SUD, being able to treat them
appropriately, and/or referring them for treatment when necessary (Finnell, et al., 2019).
According to Webster et al. (2018), there are a multitude of studies about OUD
treatment that represent the impact that continued medical education (CME) has on
provider practice. In one such study, McCalmont and colleagues (2018) demonstrate that
provider confidence regarding prescribing for pain management improved with higher
hours of recent CME on the subject. Early educational interventions have the potential to
positively impact future OUD treatment. (Webster et al., 2018).
Finnell et al. (2019) noted that the cultivation of nurse leadership requires
screening, brief intervention, and referral to treatment (SBIRT) to be integrated
into undergraduate, graduate, and postgraduate levels of training. Early educational
interventions among professionals have the potential to positively impact future OUD
treatment (Webster et al., 2018). Integration of information about the treatment of SUD is
necessary for the education of physicians and nurses. (Knudsen et al., 2011). Education
for those in the nursing field is needed on a larger scale to positively impact the bias and
stigma that nurses have toward patients with SUD (Jackman et al., 2020).
Educational modules are discussed in the paragraphs that follow. The educational
modules were implemented in two separate studies with positive results. First, in a study
conducted to address OUD management among APRNs, 670 providers viewed webinars
created for the purpose of disseminating information on OUD and the necessity for more
providers to obtain the waiver to prescribe buprenorphine as MAT. 32.5% completed
three- or six-month follow-up surveys. 18% reported obtaining the waiver within that
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period and 5.1% reported they were in the process of completing the waiver (Kameg &
Mitchell, 2020).
A similar study was done as a quality improvement project with the Veteran’s
Health Administration to empower PMHNPs to broaden treatment to veterans with OUD.
Of eleven PMHNPs surveyed to determine the need for education amongst providers to
the VA population with OUD, three had the waiver, three pursued and successfully
acquired the waiver, and ten were reported to have a plan to obtain the waiver by the
following year. The quality improvement project led to an initiative with the department
to trial buprenorphine treatment amongst VA patients presenting with OUD (Jones et al.,
2020).
The result in both scenarios suggests that education about the process for
providers to obtain the waiver to prescribe buprenorphine can be influential to close the
remaining treatment gap. It is my goal to address the needs that exist locally with a
similar survey, education, and follow-up to promote MAT access to the vulnerable
populations of rural Mississippi. Barriers other than a lack of knowledge of the waiver
were more readily apparent with this doctoral project.
Identified Needs
Mississippi provider practices are difficult to ascertain utilizing the public access
university database. Information from SAMHSA or the Mississippi Board of Nursing
might prove more useful. Documentation through the Mississippi Heroin and Opiate Task
Force does not indicate that data is being analyzed regarding providers and their
buprenorphine prescribing practices.
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Shipton et al. (2018), note that ongoing research is needed to advance the
development and production of effective alternatives for chronic non-cancer pain. Access
to prescription opioids is thought to have a significant influence on the development of
the opioid crisis (Hoffman et al., 2019). The U.S. federal government has put restrictions
and further recommendations on opioid prescribing practices to curtail their use.
Scorsone et al. (2020) acknowledge that MAT is widely available at a national
level but is utilized less frequently in rural areas. The factors underlying the limited use
rate in rural areas are not well understood (Scorsone et al., 2020). Though, stigma (Lister
et al., 2020; Sorrell et al., 2020) and reimbursement issues (Scorsone et al., 2020; Sorrell,
et al., 2020) have been identified in the reviewed research for this project as contributing
to the disparity.
Knudsen et al. (2011) note that additional research is needed to understand why
some programs with medical personnel still do not offer MAT for SUD. Findings noted
earlier might include the adherence of SUD programs to an abstinence-only approach
(Madras et al., 2020) and ignorance of the benefits of pharmacotherapy as an EBP
(Seppala, 2013; Woods & Joseph, 2017). The stigmatization of OUD and its treatment is
now well documented (Cadet & Tucker, 2019; Lister et al., 2020; Madras et al., 2020;
Scorsone et al., 2020).
Seppala (2013) promotes the utilization of partnerships between primary care
providers and outpatient addiction treatment providers. The partnership could enhance
the engagement of patients in MAT treatment. Seppala (2013) identifies a need to study
individualized treatment efforts for patients with OUD (Seppala, 2013).
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The literature reviewed identifies multiple barriers to access to pharmacotherapy
for OUD. Two main problems identified and associated with the development of this
project are the lack of providers, especially in rural areas, and the stigma associated with
OUD and its treatment. The reasons for the lack of providers vary. Common barriers for
providers to prescribe pharmacotherapy include lack of knowledge of OUD treatment or
unwillingness to prescribe OUD because addiction treatment is considered specialty care.
Concerns about reimbursement and stigma around SUD and treatment are documented in
the literature review. Early education about SUD among healthcare providers with
emphasis on the efficacy of MAT as EBP is documented as an important step in bridging
the gap in services to treat patients with OUD (Finnell et al., 2019; Tierney et al., 2020;
Webster et al., 2018).
Rationale
Theoretical Framework
The concepts and theoretical frameworks that are drawn upon for this project
include cognitive learning theory, humanistic (person-centered) psychology and learning
theory, harm reduction theory, and ethical nursing considerations. Each conceptual lens
amplifies the importance of the APRN’s acquisition of the appropriate knowledge while
having an unbiased mindset to appropriately implement pharmacotherapy for OUD. The
theories are reviewed independently and then considered collaboratively.
Cognitive Learning Theory. The basis for cognitive learning theory, originally
developed by Jean Piaget in the mid-1930s, focuses on the fact that information received
is internalized and processed by the learner using mental facilities such as thinking,
reasoning, and perceiving. According to this theory, the material to be learned should be
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clear and organized to ensure certainty for the learner as to the importance of the content
to be learned. For retention purposes, the learner should be able to relate new knowledge
to prior experiences. The incorporation of new knowledge provides more meaning when
the learner can utilize it in a familiar context. It is the cognitive learning theory that
purports that through the independent insights of the individual learner, reorganization of
perceptions and thoughts to affect one’s behavior takes place. (Butts & Rich, 2017).
Humanistic Learning Theory. Butts and Rich (2017) explain that the humanistic
learning theory in psychology focuses on the importance of the role of emotions in
learning with an emphasis on people as unique individuals with personal experiences that
influence their development. This theory necessitates growth and development in relation
to one’s own human experiences. Stigma results when society takes on a mechanistic and
detached view of individuals who are viewed as different such as people with mental
illness or substance abuse problems. (Butts & Rich, 2017). Person-centered treatment is
being integrated more frequently into healthcare settings. The emphasis on personcentered treatment lies in the foundation of humanistic psychology. The feelings of a
person, not just thoughts, are an important aspect of learning that requires an
acknowledgment of human potential and personal growth to take place. Butts and Rich
(2017) define the central theme of humanistic learning theory to be the nurturing context
that is fostered to facilitate education, therapy, and healing. (Butts & Rich, 2017)
Harm Reduction Theory. The goals of harm reduction are to reduce the adverse
effects of negative health behaviors without demanding abstinence or relinquishing the
problematic health behavior entirely. Harm reduction focuses on the problem while
actively engaging the participation of the patient. A value-neutral view of drug use and
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the patient that participates in the behavior is central to this theory. Harm reduction is a
pragmatic response to SUDs such as OUD. Pharmacotherapy for OUD is not restricted to
being labeled as a method for harm reduction, it is a viable evidence-based treatment
option. The harm reduction theoretical foundation is a necessary component of the
efficacy of pharmacotherapy for OUD (Hawk et al., 2017).
Ethical Considerations. The ethical responsibilities in advanced practice nursing
are a necessary component of the theoretical framework of this doctoral project. The
provision of medication for the chronic condition of OUD, in conjunction with other
health strategies and interventions that include counseling and simple contact with health
services, offers an improvement in quality of life (Aceijas, 2012). Physical, mental
health, and social conditions for patients improve dramatically with the use of this EBP
and should be accessible through primary care services. FNPs as well as specialists in
psychiatry should be able to knowledgeably prescribe MAT and manage the treatment of
patients requiring this evidence-based treatment. The ethical considerations associated
with advanced nursing practice include the importance of providing quality, unbiased
care and adhering to ethical principles to promote autonomy, nonmaleficence,
beneficence, and justice (Aceijas, 2012).
Autonomy is supporting patients to make informed choices. By offering evidencebased treatment solutions in an unbiased manner, the APRN is adhering to the principle
of autonomy. In doing so, the provider-patient relationship develops to assume a
collaborative approach to patient care, sharing the burden of addiction but with defined
responsibilities. The patients are entirely capable and have the right to determine how to
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proceed to manage their addiction (Aceijas, 2012) which includes a maintenance program
that continues as long as it is necessary to achieve a quality of life.
Nonmaleficence is the APRN’s responsibility to do no harm. The knowledgeable
APRN can reasonably assess that abstinence-only treatment often sets patients up for
failure. While abstinence may be an option for those with mild or short-lived addiction,
studies indicate that patients with OUD fail multiple times and may never achieve longterm sobriety utilizing the abstinence approach (Seppala, 2013). Utilization of
pharmacotherapy for OUD has been demonstrated to have the long-term achievement of
recovery in patients while they stay engaged in treatment (Seppala, 2013; Woods &
Joseph, 2017). To withhold the option of medication is harmful to a patient with chronic
illness. For APRNs not having the ability to provide this life-saving treatment due to lack
of education, lack of collaborative physician support, or due to the stigma associated with
treating SUDs is an ethical dilemma that needs to be addressed.
Beneficence is doing what is best and most helpful in-patient treatment. MAT
engages patients in the healthcare system with which they might otherwise not be
associated (Aceijas, 2012). Pharmacotherapy is the gold standard in treatment. Utilization
of medicine to treat OUD has demonstrated long-term recovery allowing patients to have
a sense of normalcy once more (Woods & Joseph, 2017).
Justice is the ethical principle of approaching patients equally and without bias. In
treating the patient population with OUD, one must consider that the condition is chronic
and alterations in the brain have resulted in a disorder that requires individualized
treatment. To consider OUD with its associated stigma is an archaic dead-end paradigm
that perpetuates the problem for people with a legitimate chronic illness.
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Collaborative Conceptual Frameworks. The educational program proposed for
this project will take into consideration the needs of the population surveyed.
Expectations based on current literature are that bias and stigma associated with OUD
and its treatment as well as lack of knowledge of how to treat OUD will be topics
necessary to address in the educational program. The cognitive learning theory is a useful
context to develop the educational program with respect to provider bias and the effect it
has on patient outcomes. The humanistic perspective acknowledges the personhood
associated with the OUD patient and all the individual experiences this patient has had.
The APRN’s responsibility is to recognize one’s own biases and how they affect ethical
standards of practice. By this, it is meant that when the APRN takes an unbiased
perspective on a patient with the chronic illness identified as OUD, they will recognize
their responsibility to educate themselves to provide evidence-based treatment utilizing
the principles of autonomy, non-maleficence, beneficence, and justice.
Specific Aims. Education should be incorporated into the training of APRNs to
be prepared on the front line of the opioid epidemic because a lack of education about
this evidence-based treatment is one of the barriers to successfully managing it. It is
well documented that neither medical schools, PA programs, nor APRN programs have a
standard of education requirement for OUD treatment. Training in medical, nursing,
and pharmacy education on OUD and MAT has been limited but is gradually
being incorporated into the education of the health professions (O’Neil, 2014). Now
that the DATA 2000 waiver is accessible to Pas and APRNs and there is new legislation
allowing for all providers to treat up to 30 patients without specialized training or
certification, the issue of standardized educational requirements needs to be addressed
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across the disciplines. As it is now, physicians require eight hours of continuing
education to obtain a MAT waiver; nurse practitioners require 24 hours. Incorporation of
pharmacotherapy for OUD into the educational curriculum for APRNs at the master’s
and doctoral levels could be a result of the proposed doctoral project.
As was noted previously in the significance of the project, interventions that
involve a web-based model to disseminate information about MAT has resulted in
successfully educating and promoting the completion of waiver training for APRNs
(Jones et al., 2020; Kameg & Mitchell, 2020). For this doctoral project,
a survey substantiated the knowledge base and attitudes about MAT
from APRNs in Mississippi. With the results of the survey, a continuing
education program was tailored for content and audience as needed using
provider’s clinical support system (PCSS) and American Psychiatric Nurse’s
Association (APNA) MAT and OUD continuing education modules as well as other
pertinent resources.
Doctor of Nursing Practice Essentials
Essential I: Scientific Underpinnings for Practice
It is necessary for doctoral-prepared APRNs to be able to implement working
knowledge of evidence-based treatment into everyday practice (American Association of
Colleges of Nursing [AACN], 2006). Utilization of science-based theories to effectively
manage barriers to the implementation of pharmacotherapy for OUD is an important facet
of advanced practice nursing’s response to the opioid epidemic. The evolving reality is
that FNPs, PMHNPs, and APRNs practicing in areas other than addiction medicine such
as the ambulatory setting, inpatient hospital setting, and emergency medicine, will
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encounter patients with OUD and need to have education on how to manage treatment
using the best evidence-based practices.
Essential II: Organizational and Systems Leadership for Quality Improvement and
Systems Thinking
It is the role of the doctoral-prepared APRN to be in a position of leadership to
implement quality improvement at a systems level (AACN, 2006). As it pertains to this
doctoral project, the results of the survey and subsequent development of an educational
program act as foundational to identifying barriers specific to Mississippi’s nurse
practitioner population. It is the aim of this doctoral project to adequately tailor and
address Mississippi APRNs’ needs to better serve patients with OUD across multiple
settings including, but not limited to, emergency departments, inpatient psychiatric units,
family practices, and obstetrics practices.
Essential III: Clinical Scholarship and Analytical Methods for Evidence-Based Practice
Doctoral-prepared APRNs are expected to utilize scholarship and research to
synthesize research findings for utilization in practice (AACN, 2006). Solving a problem
by utilizing an integrated knowledge base is inherent to this work. This doctoral project
promotes the utilization of evidence-based practices in OUD treatment by identification
of the barriers to the utilization of MAT amongst Mississippi APRNs.
Essential VII: Clinical Prevention and Population Health for Improving the Nation’s
Health
This doctoral project aimed to identify barriers specific to Mississippi APRNs and
implemented a continuing education program tailored to the findings to positively affect
the nation’s health. The opioid crisis remains an ongoing problem for which providers
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must be adequately prepared to participate by knowledgeably offering evidence-based
treatment. This project addresses clinical prevention and population health for the
improvement of the health of citizens of the U.S. (AACN, 2006).
Summary
OUD is a problem that affects Mississippi because the population is mostly rural
and underserved. Evidence points to the need for education of providers to reduce the
stigma of SUD and promote the utilization of pharmacotherapy for OUD with appropriate
training and support. Education to reduce stigma and the promotion of pharmacotherapy
is especially important considering the recent legislation that enables APRNs to prescribe
buprenorphine without getting a certification. A concern remains, though, that the
collaborative agreement required for APRNs to practice in Mississippi may continue to
act as a barrier. A survey was used to determine the APRNs’ knowledge of OUD and its
evidence-based treatment, while barriers were assessed that influence the degree of
engagement of Mississippi APRNs in the provision of this life-saving treatment. A
continuing education module was designed and tailored to the needs that are revealed by
the survey. The educational module will be published through The University of
Southern Mississippi.
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CHAPTER II –METHODOLOGY
Context
The project was a descriptive design for which APRNs were surveyed to
determine barriers to prescribing pharmacotherapy for OUD. Nurse practitioners and
physician assistants are leading the way in prescribing pharmacotherapy for
OUD. However, barriers remain that interfere with meeting the need for
pharmacotherapy treatment in patients with OUD. Information is lacking on specific
practices for Mississippi APRNs; however, studies indicated that prescription of
pharmacotherapy is lacking in rural areas (Jones & McCance-Katz, 2018). This doctoral
project’s aimed to gain information on what barriers exist in Mississippi that needs to be
alleviated for better access to the gold standard treatment of OUD.
Intervention
The intervention involved the development of a survey for FNPs and PMHNPs in
Mississippi. The results informed the development of a continuing education program
guided by the responses. Stigma and lack of knowledge of OUD treatment are addressed
in the continuing education program module. The module was developed with future
APRN students’ needs in mind, as well as to promote the inclusion of the program into
university curriculums.
Intervention
While all APRNs may prescribe pharmacotherapy for OUD, it is typically a
practice reserved for addiction treatment specialists. Addiction treatment in Mississippi is
often FNPs, although PMHNPs often encounter patients with opioid addiction due to the
comorbidity of substance abuse and mental health issues. Therefore, the population for
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this doctoral project was FNPs and PMHNPs registered with the Mississippi Board of
Nursing.
The sample was self-inclusive of FNPs and PMHNPs that responded to the
surveys that were sent out via email communications. The University of Southern
Mississippi (USM) College of Nursing and Health Professions, School of Leadership and
Advanced Nursing Practice the setting for this doctoral project. The survey was
developed collaboratively to assess APRN knowledge and bias pertaining to
OUD. Ethical Considerations
Personal information on nurse practitioners in Mississippi was provided by the
Mississippi Board of Nursing. Names, addresses, email addresses, and other personal
information for these practitioners were used only for the purpose of the survey proposed.
The information was maintained in a locked office and was shredded and discarded
appropriately at the close of the doctoral project.
Project Timeline
The doctoral project commenced upon The University of Southern Mississippi’s
Institutional Review Board approval for the doctoral project (Protocol # 21-242).
Mississippi Board of Nursing provided the information for APRNs in Mississippi for
which surveys were sent. A follow-up email was sent at two weeks and four weeks
respectively. The project was closed after the survey results were received during the
four-week project.
Summary
It is essential that APRNs have education on OUD treatment as it is the gold
standard for treatment, yet it is underutilized, especially in rural America. The doctoral
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project ascertained information from APRNs in Mississippi as to what barriers remain
specific to Mississippi APRNs’ prescription of pharmacotherapy for OUD. A continuing
education program was developed to be disseminated by USM and made available to
future students to address evidence-based OUD treatment.
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CHAPTER III -RESULTS
This chapter analyzes the results of the survey conducted to determine barriers to
prescribing pharmacotherapy for OUD amongst Mississippi APRNs in family and
psychiatric specialties. The frequencies from Qualtrics were analyzed to assess the need
for education of APRNs on pharmacotherapy for OUD. Three hundred and two APRN
respondents took part in the survey. Two-hundred-fifty-eight respondents completed the
survey in its entirety. The survey included questions relating to the stigma associated with
patients who have an addiction, inclusivity of opioid addiction pharmacotherapy in the
educational curricula of nurse practitioners, subjective perception of competency to
prescribe pharmacotherapy for OUD, and perception of reduced practice to require a
physician collaborative agreement. Demographic information was also collected from the
participants including gender, age, nursing education, and ethnic background.
Results-Details of the Process, Measures, and Outcomes
A survey was conducted to assess the needs of Mississippi APRNs regarding
education on pharmacotherapy for OUD. Informed consent was obtained from
prospective participants in the introduction to the Qualtrics survey. Mississippi Nurse’s
Association (MNA) supported this doctoral project research by publishing a one-time
notice to its members to promote participation in the survey. Before the doctoral project
began, the Mississippi Association of Nurse Practitioners (MANP) agreed to publish a
notice, however, this did not occur before the end of the doctoral project. A list of all the
APRNs in Mississippi was purchased by the primary investigator from the Mississippi
Board of Nursing (BON) using a grant the primary investigator was awarded by the
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Gamma Lambda Chapter of Sigma Theta Tau International Honor Society of Nursing
through The University of Southern Mississippi.
Context
The primary investigator developed a list from the 7,141 APRNs provided in the
BON documentation that was current as of November 2021. Certified registered nurse
anesthetists (CRNAs) and certified nurse midwives (CNMs) were eliminated from the
original email list. Due to the generality of the designation of “nurse practitioner” for the
remainder of the APRNs on the list, the primary investigator was unable to discern what
specialty each nurse practitioner was certified in. Therefore, an email list was developed
to include all the remaining APRNs. The email to recruit doctoral project research
participants was sent out to the APRNs on the developed list. Reminder emails were sent
out two weeks and four weeks after the initial request for participation. The email
indicated that the survey was to be completed by family and psychiatric nurse
practitioners only. Several email responses were received by the primary investigator
from APRNs who were interested in participating but acknowledged they were certified
in specialties other than family and psychiatry. These individuals were thanked for their
interest but directed not to participate in the study.
The continuing education program will be utilized to disseminate the survey
results and offer education from this preliminary research. Objectives for the educational
module include that participants will recognize barriers to treatment of OUD. Participants
will understand the difference between OUD and opioid dependence. Participants will
identify evidence-based practices for the treatment of OUD. Participants will identify
resources for appropriate referrals. Participants will understand the basics of how to
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initiate and maintain treatment with buprenorphine products. Lastly, participants will
utilize resources for further learning.
Presentation of the Results
A 36-question survey was developed in Qualtrics and sent via email to 6,088
certified advanced practice nurses registered in Mississippi. Duplicate responses were
prevented by utilizing Qualtrics’ detection of ISP addresses. Of the 302 recorded
responses, the response quality was 99%. No evidence was detected by Qualtrics of bots
taking the survey.
Most respondents (74.42%) were master’s prepared clinicians, 12.02% were
DNP-prepared clinicians, and 8.53% had a post-master’s certificate. One respondent had
a Doctor of Nursing Science (DNS), six respondents had a Doctor of Philosophy (Ph.D.)
and the remaining six respondents responded as “other” (which could include clinical
nurse specialists). FNPs made up 80.21% of respondents and 19.79% were PMHNPs.
Family practice accounted for 32.68% of the respondents while 36.58% were in practice
in other specialties. The specialties included ambulatory, inpatient or outpatient
psychiatric, and inpatient geriatric psych. Urgent care, pediatrics, minor medical, and
school nursing environments were listed as other practice settings indicated by
respondents. Prescribers of opioids made up 59.3% of respondents.
The demographics were as follows: primarily female (82.49%), with the other
15.9% being male, one respondent was transgender, one respondent identified as other,
and two respondents preferred not to disclose their gender. White or European American
accounted for 74.42% of the respondents, 19.77% of respondents were black or African
American, two respondents were Asian, three respondents were American Indian or
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Alaskan Native, two were Latino/Hispanic, three respondents identified as unknown
ethnicity, and five respondents identified as other.
Current practices addressed whether the APRNs prescribed opiates and used
screening tools to detect OUD or opioid dependence before prescribing opiates. Ninetytwo percent of respondents indicated that they had a DEA number. Ninety-one percent of
respondents recognized the importance of screening for opioid addiction prior to
initiating opioid treatment. Seventy-three percent indicate that they screen for opioid
addiction, whether they prescribe opioids. Ninety-nine percent of respondents were
familiar with the opioid crisis. Eighty-eight percent of respondents indicated that they
understood opioid addiction is a problem in Mississippi. Seventy-four percent of
respondents recognize that OUD is a disease.
In terms of assessing stigma, 64% of respondents believed that people with
addiction definitely or probably are manipulative and 73% believed that people with
addiction are definitely or probably more likely to lie to get what they want. Seventy-two
percent of respondents acknowledged that there is healthcare bias toward people with
addiction disorders while only 32% admitted to their own bias toward people with
addiction.
Regarding the assessment of nursing education addressing the evidence-based
prescription of OUD treatment in higher education programs, 37% of respondents
acknowledged that they definitely or probably learned how to adequately treat OUD in
school. Sixty-two percent of the respondents could not recall whether pharmacotherapy
for OUD was covered in their higher education curriculum. Seventy-three percent
believed they know the difference between opioid dependence and OUD.
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Mixed results were found when the data were analyzed regarding the assessment
of interest for Mississippi APRNs to prescribe pharmacotherapy for OUD. The legislation
allows for providers to treat up to 30 patients without the DATA X waiver or additional
training. Despite this change in federal policy to promote pharmacotherapy for OUD,
67% of respondents were unaware of the legislation. Twenty-one percent of respondents
already currently treat OUD with pharmacotherapy. This finding was surprising to the
investigator and the doctoral chair. Despite the ability to prescribe without red tape, only
28% of respondents indicate they definitely or probably want to prescribe
pharmacotherapy for OUD.
Mixed results were received on the interest of APRNs getting more education
through a free continuing education program addressing pharmacotherapy for OUD to
promote confidence and ability to prescribe competently for up to thirty patients. Thirtynine percent of respondents said they were probably or definitely interested. Forty-one
percent of respondents indicated that they were probably or definitely not interested.
Nineteen percent of respondents indicated they may be interested, but it depends on other
factors.
Questions were analyzed by the primary investigator that addressed the current
practices of Mississippi APRNs. Twenty-nine percent of respondents indicated that they
very often or frequently encounter people in need of counseling referrals. Sixty-seven
percent indicated that they refer cases of opioid abuse for counseling. Twenty percent of
respondents reported that they very often or frequently encounter patients in need of
pharmacotherapy for OUD. Thirty-three percent of respondents indicated they very often
or frequently encounter patients who require treatment for OUD. Fifty-nine percent of
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respondents indicated that they refer patients outside their practice for pharmacotherapy
when required. Thirty-two percent of respondents indicated pharmacotherapy resources
are often or frequently available. Forty percent indicated they are only sometimes
available.
Observed Associations and Unintended Consequences
The benefits of the doctoral project include that an initial attempt was made to
ascertain information on current practices of Mississippi APRNs in the prescription of
pharmacotherapy for OUD. Furthermore, a benefit of this doctoral project’s research is
that preliminary information was gathered on potential barriers to the treatment of OUD
in Mississippi. This doctoral project provided the foundation for further investigation into
barriers toward the utilization of gold standard treatment for OUD.
One identified problem with the survey is the way some questions were asked.
Some questions were inclusive of all respondents when they should have targeted only
those that responded a certain way. Question #8 asked: Do you use a screening prior to
prescribing opioids in your practice? This question surveyed all APRNs regardless of
whether they prescribe opioids. The question would have elicited more information if it
had only been targeted toward those who prescribe opioids. In this manner, the question
would have given insight into the percentage of respondents who use screening tools
before prescribing opiates.
Another survey question was worded: Is addiction a disease? The wording for this
question presupposes that the APRN knows the difference between illness and disease. A
better way to ask this question would have involved asking whether the respondent
agrees with the definition of a disease. Once the primary investigator defines the term
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disease, respondents would then either agree or disagree with the definition and, in this
way, more clearly respond.
Other than the wording of some questions in the survey, a limitation of the
doctoral project included the inability to obtain a good response from about 15% to 20%
of APRNs. The promotion of the doctoral project by MANP to further disseminate
recruitment is an identified limitation. This organization has been found to reach a
different population of APRNs than MNA.
The cost of the study was $250. The grant was awarded to the primary
investigator by Sigma Theta Tau International Honor Society of Nursing for the expense
associated with procuring the list of advanced practice nurses. The list was provided by
the BON.
Details of Missing Data
The survey respondents’ personal, sensitive information was maintained
confidentiality. Only relevant information was collected and analyzed by the primary
investigator. This doctoral project produced no missing data. Survey results were
downloaded and stored in a password-protected file.
Summary
In conclusion, this doctoral project was focused on ascertaining information about
potential barriers to prescribing evidence-based treatment for OUD by APRNs in
Mississippi. Survey results provided a variety of information about barriers to the
prescription of medication for the treatment of OUD by APRNs in Mississippi. Stigma
remains a problem in addiction treatment. Education of pharmacotherapy is not well
covered in advanced practice nursing curricula so APRNs feel unprepared to treat OUD.
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Pharmacotherapy is underutilized for patients with OUD in Mississippi. Providers are
unaware that they do not have to undergo more education (i.e., DATA X waiver) to
prescribe buprenorphine to up to 30 patients with OUD. Interest is low in terms of
APRNs wanting to prescribe treatment for OUD in their practice. The reduced practice
status of APRNs may limit the ability of these providers to prescribe evidence-based
treatment for patients who require it. A continuing education program was developed
based on the identified needs from the doctoral project survey results and will be
available through The University of Southern Mississippi.
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CHAPTER IV – DISCUSSION
Introduction
This chapter is an analysis of the results obtained from the project survey. The
survey results were analyzed by the investigators. Recommendations will be given with
the interpretation of the key findings from the survey. Implications for future practice will
be considered and the limitations of the doctoral project will be noted. Prior to the
conclusion of this chapter, dissemination of the work will be discussed.
Recommendations
The doctoral project survey offered insight into the current practices of nurse
practitioners in Mississippi regarding pharmacotherapy for OUD and referral for
counseling; utilization of screening tools before prescribing opiates was also explored.
The doctoral project survey provided information on respondents' view of stigma in
health care, the practitioners’ own bias toward people with addiction, and their view of
whether the collaborative agreement hinders pharmacotherapy prescription for OUD in
Mississippi. Furthermore, the doctoral project survey offered information on higher
education curricula inclusion of pharmacotherapy training, and nurse practitioners’
perceived confidence and competency to prescribe pharmacotherapy for OUD.
Current practices associated with pharmacotherapy for OUD amongst respondents
reflect the minority, 21.79%, who already prescribe pharmacotherapy for OUD. This
information is limited in that we do not know whether they prescribe naltrexone,
buprenorphine, or methadone. Roughly 29% of respondents expressed an interest in
prescribing pharmacotherapy, but the question was not limited to only those who do not
already provide pharmacotherapy. We can assume that the difference between those who
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already prescribe pharmacotherapy for OUD (21.79%) and those who have the interest to
prescribe (29%) results in identifying only 8% of respondents who have an interest in
starting this practice. This is congruent with research findings that people in rural areas
have minimal access to evidence-based treatment.
Sixty-three percent of respondents selected that they very often, frequently, or
sometimes encounter people who meet the criteria for OUD. Fifty-nine percent of
respondents indicate that they refer out for pharmacotherapy. We cannot assume that the
remaining respondents do not refer out, because they may be the individuals that
indicated that they rarely or never encounter patients with OUD. They may not recognize
OUD because of a lack of screening tools despite whether they prescribe opioids. Only
32% responded that pharmacotherapy options were often or frequently available. We
must take into consideration that there are occasions in which OUD may be identified,
but pharmacotherapy is not an option for a lack of resources.
There is more propensity toward referrals for counseling with 67% of respondents
indicating that they refer patients for counseling as it relates to misuse of opioids as
compared to the 59% of respondents that refer out for pharmacotherapy for OUD. The
literature generally supports pharmacotherapy with empirical scientific evidence as the
gold standard of treatment. While counseling can also be utilized for maintenance, it is a
substandard primary treatment. The reasons for lack of referral to pharmacotherapy for
OUD that we can infer based on the literature are that 1) providers are unaware of the
evidence-based treatment for OUD; 2) providers do not have access to evidence-based
treatment (pharmacotherapy) for OUD but do have access to counselors; 3) providers
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reject the evidence-based treatment due to associated stigma and a lack of desire to treat
patients with OUD.
The results of the survey showed that APRNs identified that there is a high level
of stigma in health care associated with people who have addictions. Despite recognition
of stigma, there was low reported personal bias reflected in the respondents when asked
whether they recognize having a bias toward people with addiction. This discrepancy
could either indicate that respondents who were interested in participating in a survey on
pharmacotherapy for OUD have lower rates of stigmatization towards people with
addiction, or it could indicate that respondents do not recognize their stigmatizing
characterizations toward people with addiction. A high degree of survey responses
characterized people with addiction to be more capable of lying and manipulating to get
what they want. With this information, the primary investigator recognizes that there may
be respondents who were not fully aware of inherent bias toward this population.
Eighty-two percent of the respondents acknowledged that the physician with
whom they had a collaborative agreement did not treat OUD with
pharmacotherapy. While this overwhelming majority reflects the findings in the
literature that pharmacotherapy for OUD is not readily provided in rural areas like
Mississippi, respondents indicated working in various settings. Addiction medicine is
considered a specialty and it would be unusual for specialties such as gastroenterology or
cardiology to treat OUD. Twenty-one percent of respondents recognized that the
physician with whom they had a collaborative agreement was definitely or probably
willing to treat OUD with pharmacotherapy. While it appears that this small percentage
reflects the lack of evidence-based treatment of OUD amongst APRNs in Mississippi, the
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result must be interpreted considering the population of APRNs responding to the study.
Over a third of the respondents' practice in specialties in which OUD treatment is not
typically undertaken.
Eighty-eight percent of respondents believe APRNs with several years of
experience should be able to practice to the full extent of their practice scope without the
hindrance of a required physician collaboration. If full practice for APRNs in Mississippi
was to be adopted, APRNs who are in high demand in rural areas due to the lack of
physicians would be able to fill in the gaps where needed. APRNs who are interested in
pharmacotherapy for OUD but are limited by the lack of physician collaborators who are
willing to treat OUD with evidenced based practice would be free to do so.
Thirty-six percent of respondents could confirm that their higher education
curricula covered best practices in one or more of the medications (methadone,
buprenorphine, naltrexone) utilized for the treatment of OUD. This reflects the AANC’s
concern that pharmacotherapy for OUD is not being covered in higher education
curricula which leaves APRNs with poor preparation to meet the needs of patients
suffering from the opioid epidemic. Sixty-five percent of respondents indicated that they
were probably or definitely not interested in prescribing treatment for OUD. The reason
behind the disinterest in prescribing pharmacotherapy for OUD could be related to not
having a willing collaborator, not having an interest in the population, having associated
stigma towards people with addiction, not feeling competent in prescribing treatment, or
other factors not explored in this doctoral project.
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Implications for Future Practice
Reduced practice restricts experienced APRNs from utilizing their full scope of
practice because they must rely on the credentials and interests of an available physician
collaborator. If a physician is uninterested or unwilling to participate in the provision of
pharmacotherapy for OUD, then the APRN who has a collaborative agreement with the
physician must seek other arrangements for collaboration. Lack of physician interest can
be a barrier to prescribing pharmacotherapy for OUD in Mississippi where the demand
for APRNs is high due to the lack of physicians, especially specialists, in the rural areas
of the state. While we acknowledge the benefit of a collaborative agreement for new
APRNs with an individual of higher education or more clinical experience (an
experienced APRN of the same discipline), a prolonged arrangement in which an APRN
is required to maintain a physician collaborator is potentially a barrier to practice as
evidenced by the results of the survey.
Higher education programs need to address pharmacotherapy for OUD in
program studies across APRN disciplines to include family and psychiatric nursing
specialties. Utilization of pharmacotherapy for OUD is also important in acute APRN
studies. This was demonstrated with the 62.83% of APRN respondents who could not
recall whether their higher education curricula covered pharmacotherapy for OUD.
The stigma associated with addictions remains a problem that should be addressed
in the education of APRNs. Reflection on one’s own biases should be addressed in higher
education programs. This practice promotes mindfulness in the therapeutic relationship
that is inherent in the nurse-patient interactions regardless of whether it is psychiatric,
primary care, or acute nursing practice.
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Limitations
Several limitations of this survey were identified by the investigators. The survey
addressed multiple topics associated with pharmacotherapy for OUD to assess areas of
needed education amongst nurse practitioners. The very nature of the purpose of the
doctoral project could be considered a limitation because covering just one topic
associated with pharmacotherapy could have provided more focused responses.
Subsequent follow up surveys would be beneficial in each of the following areas: stigma,
higher education, opiate prescribing practices, pharmacotherapy practices, and referrals
for counseling. However, continued solicitation of responses with the same APRNs might
inhibit further engagement and skew the results.
Another limitation of the doctoral project was the number of participants. Ideally,
we want to see about 15% to 20% participation. Amongst 6,088 nurse practitioners, it is
undetermined as to how many of those nurse practitioners are certified in family and
psychiatric specialties. We can determine that 15% to 20% of that 6,088 did not respond,
though, because we would require 912 responses to meet the 15% minimum. However,
all 6,088 nurse practitioners were not family or psychiatric nurse practitioners; other
specialties were included amongst them. Because we were unable to identify those in the
specialties we were attempting to survey, it may have been better to survey all nurse
practitioners except for CNMs and CRNAs.
Lastly, a limitation of the doctoral project is that the APRNs who responded were
not tracked. This might have been an advantage of the doctoral project in one respect
because some APRNs may have chosen not to participate if it was tracked. From another
perspective, though, if this doctoral project was able to determine which respondents had
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an interest in the treatment of patients with pharmacotherapy for OUD, this investigator
could follow up more strategically.
Dissemination
The dissemination of the results of this survey will be achieved through various
platforms. First, the primary investigator presented findings on DNP Scholarship Day and
published them in USM’s digital repository, Aquila. Second, the results will be
disseminated in the continuing education module that will be accessible through The
University of Southern Mississippi.
The primary investigator will present findings associated with this survey at a
national conference of the American Association for Nurse Practitioners (AANP) in the
summer of 2023 and to the Sigma Theta Tau International Honor Society of Nursing. The
findings will be disseminated by submission of a poster presentation for nurse
practitioners across the U.S. to have access to this information. The educational module
will be referenced for nurse practitioners to access as well.
Conclusion
This survey explored a range of topics associated with pharmacotherapy for OUD
to assess the current practices of APRNs in Mississippi, examine stigma toward people
with addiction, determine interest in prescribing pharmacotherapy for OUD, and assess
whether higher education covers pharmacotherapy for OUD. APRNs are at the forefront
of the opioid epidemic and should be prepared to utilize gold standard treatment for
OUD, therefore, the primary purpose of the doctoral project was to assess potential
barriers to utilizing evidence-based practices for the treatment of OUD amongst
Mississippi APRNs. The doctoral project reflected findings in the literature regarding the
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lack of provision of evidence-based practices for the treatment of OUD in rural areas. A
continuing education program presented the findings of this survey and addressed the
identification of OUD, screening tools to utilize in various practice settings, and initiation
recommendations for buprenorphine in the outpatient clinical (primary and psychiatric)
and ambulatory settings. Further, in-depth resources were provided in the educational
module for the benefit of the learner. Referral practices after initiation of buprenorphine
were also discussed. The purpose of the continuing education program is to target the
needs of Mississippi APRNs to promote the utilization of pharmacotherapy for OUD as
the gold-standard treatment. As full practice authority is obtained for Mississippi APRNs,
hopefully, treatment with pharmacotherapy for OUD will become more available to those
who need it.
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APPENDIX A – Survey
Institutional Review Board Standard Online Informed Consent
Project Information
Title: DNP Project: Pharmacotherapy for OUD treatment in Mississippi
Principle Investigator: Amanda Whitacre; 601-315-9382; amanda.whitacre@usm.edu
Co-Principal Investigator: Dr. Marti Jordan,601-266-5527, marti.jordan@usm.edu
College: College: Nursing and Health Professions
School and Program: Leadership and Advanced Nursing Practice
Research Description: Purpose: The results sought for this study are to ascertain
information from Advanced Practice Registered Nurses (APRNs) in the psychiatric and
family nurse practice specialties in Mississippi to determine educational needs to promote
best practices in pharmacotherapy for opioid use disorder (OUD). The information we are
seeking relates to APRN education and understanding of OUD and evidence-based
treatment for this substance use disorder. FNPs and PMHNPs will encounter patients
with OUD in their practice across the ambulatory, primary care, and psychiatric settings.
It is imperative that FNPs and PMHNPs recognize symptoms of OUD and are
knowledgeable about evidence-based treatment. The investigator-developed survey will
be used to collect information from Family Nurse Practitioners (FNPs) and Psychiatric
Mental Health Nurse Practitioners (PMHNPs) in Mississippi with respect to knowledge
and practice in the prescription of pharmacotherapy for OUD. The researcher will
specifically look at descriptive statistics in terms of frequencies.
Description of the Doctoral Project The survey will take about ten minutes to complete.
An email reminder will be sent at two weeks and four weeks to ensure maximum
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participation amongst FNPs and PMHNPs in Mississippi to ascertain the best results for
analysis and development of a continuing education module. The number of participants
expected is approximately 115. There are no restrictions on normal activities or invasive
techniques to disclose.
Benefits: As a result of participation in the study you will be made aware of and provided
access to a continuing education module developed from the results of this survey that is
tailored to the needs of Mississippi APRNs. Risks: There are no identified risks
associated with participation in this survey.
Confidentiality: Physical data will be locked in a drawer in the researcher's office and
electronic data will be password protected. The physical data will be shredded and
discarded after that research is complete. Password protection will keep the results of the
survey safe. The list of APRNs will be shredded and disposed of according to university
policy and the results of the survey will be deleted upon completion of the analysis of the
data and submission of the final project.
Alternative Procedures: No alternative to the survey is offered for this project.
Participant’s Assurance: This project and this consent form have been reviewed by the
Institutional Review Board, which ensures that research projects involving human
subjects follow federal regulations.
Any questions or concerns about rights as a research participant should be
directed to the Chair of the Institutional Review Board, The University of Southern
Mississippi, 118 College Drive #5125, Hattiesburg, MS, 39406-0001, 601-266-5997.
Any questions about this research project should be directed to the Principal Investigator
using the contact information provided above.
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CONSENT TO PARTICIPATE IN RESEARCH:
I understand that participation in this project is completely voluntary, and I may withdraw
at any time without penalty, prejudice, or loss of benefits. Unless described above, all
personal information will be kept strictly confidential, including my name and other
identifying information. All procedures to be followed and their purposes were

Q1 Consent to participate in research: By clicking the box below, I give my consent to
participate in this research project. If you do not wish to participate in this doctoral
project, please close your browser now.
o Yes, I consent to participate
o No, I do not consent to participate. Please close your browser now.
Q2 Please indicate licensure specialty by selecting all that apply.
o Family Nurse Practitioner
o Psychiatric Mental-Health Nurse Practitioner
Q3 Please indicate the level of nursing education by selecting the highest level that
applies.
o
o
o
o
o
o

Master of Nursing (MSN)
Post-master's certificate
Doctor of Nursing Science (DNS)
Doctor of Nursing Practice (DNP)
Doctor of Philosophy (Ph.D.)
Other __________________________________________________

Q4 Please indicate the type of setting in which you currently practice by selecting all that
apply.
o
o
o
o
o
o

Ambulatory
Inpatient psychiatric
Inpatient geriatric-psychiatric
Outpatient psychiatric
Family practice
Other
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Q5 Do you have a DEA number?
o Yes
o No
Q6 Do you prescribe opioids in your practice?
o Yes
o No
Q7 Do you believe it is important to use screening practices before initiating an opioid
prescription in practice?
o
o
o
o
o

Definitely important
Probably important
Might or might not be important
Probably not important
Definitely not important

Q8 Do you use a screening prior to prescribing opioids in your practice?
o Yes
o No
Q9 Are you familiar with the opioid crisis?
o Yes
o No
Q10 Do you believe opioid addiction is a problem in Mississippi?
o
o
o
o
o

Definitely a problem
Probably a problem
Might or might not be a problem
Probably not a problem
Definitely not a problem

Q11 Do you believe addiction is a disease?
o
o
o
o
o

Definitely is a disease
Probably is a disease
Might or might not be a disease
Probably not a disease
Definitely not a disease
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Q12 Do you feel that patients with addiction are generally manipulative?
o
o
o
o
o

Definitely manipulative
Probably manipulative
Might or might not be manipulative
Probably are not manipulate
Definitely are not manipulative

Q13 Do you feel that patients with addiction are more likely to lie to get what they want?
o
o
o
o
o

Definitely yes
Probably yes
Might or might not
Probably not
Definitely not

Q14 Do you believe that healthcare providers show bias toward patients with addiction
disorders?
o
o
o
o
o

Definitely
Probably
Might or might not
Probably not
Definitely not

Q15 Do you acknowledge any personal bias toward patients who have addiction?
o
o
o
o
o

Definitely
Probably
Might or might not
Probably not
Definitely not

Q16 Did your higher education nursing curriculum prepare you to manage the treatment
of opioid use disorder (OUD)?
o
o
o
o
o

Definitely did
Probably did
Might or might not
Probably did not
Definitely did not
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Q17 Do you know the difference between OUD and opioid dependence?
o
o
o
o
o

Definitely do
Probably do
Might or might not
Probably do not
Definitely do not

Q18 Do you currently use pharmacotherapy for the treatment of patients who meet the
criteria for the Diagnostic and Statistic Manual (DSM) 5 diagnosis of OUD?
o Yes
o No
Q19 <div>If you do not already prescribe pharmacotherapy for the treatment of OUD, do
you have any interest in treating patients with OUD?
o
o
o
o
o

Definitely yes
Probably yes
Might or might not
Probably no
Definitely no

Q20 How often do you encounter patients that need addiction treatment as it relates to
abuse of opioids?
o
o
o
o
o

Very often
Frequently
Sometimes
Seldom
Rarely

Q21 Do you refer patients outside your practice for abuse of opioids that utilizes
pharmacotherapy such as methadone or suboxone?
o Yes
o No
Q22 How often do you encounter patients you assess to be in need of pharmacotherapy
for OUD?
o Very often
o Frequently
o Sometimes
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o Seldom
o Not at all
Q23 How readily available are pharmacotherapy resources (methadone treatment facility
or outpatient suboxone provider) for you to refer patients who need OUD treatment?
o
o
o
o
o

Pharmacotherapy resources are often available
Pharmacotherapy resources are frequently available
Pharmacotherapy resources are sometimes available
Pharmacotherapy resources are seldom available
Pharmacotherapy resources are never available

Q24 Do you refer patients outside your practice for counseling related to substance abuse
that includes opioid abuse?
o Yes
o No
Q25 How often do you encounter patients you assess to need a referral for counseling
related to opioid abuse?
o
o
o
o
o

Very often
Frequently
Sometimes
Seldom
Not at all

Q26 Are you aware that in April 2021 new national legislation grants nurse practitioners
with a DEA number the ability to prescribe pharmacotherapy for OUD, for up to 30
patients without obtaining additional certification/training or a DATA-2000 waiver?
o Yes
o No
Q27 Are you interested in prescribing suboxone in your practice now that legislation
allows nurse practitioners to do so without special training?
o
o
o
o
o

Definitely yes
Probably yes
Might or might not
Probably not
Definitely not
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Q28 Did your education cover initiation and maintenance prescribing of methadone,
buprenorphine, and/or naltrexone? Select all that apply.
o
o
o
o
o

Yes, initiation and maintenance of methadone prescribing best practices
Yes, initiation and maintenance of buprenorphine prescribing best practices
Yes, initiation and maintenance of naltrexone prescribing best practices
None of the above
I do not know/I do not recall

Q29 Would you be interested in an educational module that would prepare you to earn
CEUs, match you with a mentor, and educate you on initiation and maintenance
prescribing best practices so that you could feel confident in identifying and competently
prescribing suboxone for patients with OUD?
o
o
o
o
o

Definitely interested
Probably interested
Maybe interest depends on other factors
Probably not interested
Definitely not interested

Q30 Do the physicians with whom you have a collaborative agreement treat OUD with
pharmacotherapy?
o Yes
o No
Q31 Are the physicians with whom you have a collaborative agreement willing to treat
patients with OUD?
o
o
o
o
o

Definitely yes
Probably yes
I am not certain
Probably not
Definitely not

Q32 Should nurse practitioners with several years' experience have the autonomy to
practice with full authority in Mississippi?
o
o
o
o
o

Definitely yes
Probably yes
Might or might not
Probably not
Definitely not

72

Q33 Does the collaborative agreement with a physician limit your ability to practice
advanced practice nursing to the full capacity you believe you are capable, of and to the
extent you have been adequately trained?
o
o
o
o
o
o

Definitely yes
Probably yes
I do not know
Probably not
Definitely not

Q34 With which gender do you most closely identify?
o
o
o
o
o

Male
Female
Transgender
Prefer not to say
Other

Q35 Which of the following ethnicities best describes you?
o
o
o
o
o
o
o
o

White or European American
Black or African American
American Indian or Alaskan Native
Asian
Native Hawaiian or Pacific Islander
Latino/Hispanic
Unknown
Other

Q36 What is your age range?
o
o
o
o
o
o
o

21-30
31-40
41-50
51-60
61-70
71-80
81-90
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